Antimalarial drug resistance is a serious international health problem and a major obstacle for malaria control efforts in Africa. A better understanding of the epidemiology and molecular mechanisms of antimalarial drug resistance is greatly needed. The overall goal of this project is to use clinical and laboratory studies to critically evaluate practical first-line therapies for uncomplicated malaria in a cohort of Ugandan children living in an area of high malaria endemicity.
The specific aims of the project are: 1) to compare the efficacy of chloroquine, amodiaquine, and Fansidar as first-line agents for the treatment of uncomplicated falciparum malaria, 2) to use molecular epidemiologic tools to distinguish recrudescence from reinfection after antimalarial therapy, and 3) to correlate drug resistance with mutations in Plasmodium genes that may mediate resistance. Patients be randomized to three different first-line drug regimens and followed prospectively for 18 months to compare impact each regimen has on a number of primary and secondary clinical outcomes. For each documented case of malaria, and at serial time points, blood samples will be collected for isolation of parasite DNA. This material will allow us to genotype parasites over time, and thus determine if parasites that appear after therapy due to recrudescence of resistant parasites or reinfection. In addition, parasite DNA will be used to determine whether polymorphisms in key parasite genes mediate resistance. The results of these investigations will provide key information for the formulation of rational malaria treatment policies and contribute to our understanding of the mechanisms of antimalarial drug resistance.

Agency
National Institute of Health (NIH)
Institute
Fogarty International Center (FIC)
Type
Research Scientist Development Award - Research & Training (K01)
Project #
5K01TW000007-03
Application #
6394896
Study Section
International and Cooperative Projects 1 Study Section (ICP)
Program Officer
Jessup, Christine
Project Start
1999-09-30
Project End
2003-08-31
Budget Start
2001-09-01
Budget End
2003-08-31
Support Year
3
Fiscal Year
2001
Total Cost
$102,600
Indirect Cost
Name
University of California San Francisco
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
073133571
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Roxby, Alison C; Ben-Youssef, Leïla; Marx, Grace et al. (2016) Dual contraceptive method use in HIV-serodiscordant Kenyan couples. J Fam Plann Reprod Health Care 42:264-270
Tusting, Lucy S; Bousema, Teun; Smith, David L et al. (2014) Measuring changes in Plasmodium falciparum transmission: precision, accuracy and costs of metrics. Adv Parasitol 84:151-208
Mabuka, Jennifer; Goo, Leslie; Omenda, Maxwel M et al. (2013) HIV-1 maternal and infant variants show similar sensitivity to broadly neutralizing antibodies, but sensitivity varies by subtype. AIDS 27:1535-44
Gantt, Soren; Huang, Meei-Li; Magaret, Amalia et al. (2013) An artesunate-containing antimalarial treatment regimen did not suppress cytomegalovirus viremia. J Clin Virol 58:276-8
Nsobya, Samuel L; Dokomajilar, Christian; Joloba, Moses et al. (2007) Resistance-mediating Plasmodium falciparum pfcrt and pfmdr1 alleles after treatment with artesunate-amodiaquine in Uganda. Antimicrob Agents Chemother 51:3023-5
Dokomajilar, Christian; Nsobya, Samuel L; Greenhouse, Bryan et al. (2006) Selection of Plasmodium falciparum pfmdr1 alleles following therapy with artemether-lumefantrine in an area of Uganda where malaria is highly endemic. Antimicrob Agents Chemother 50:1893-5
Francis, Damon; Nsobya, Samuel L; Talisuna, Ambrose et al. (2006) Geographic differences in antimalarial drug efficacy in Uganda are explained by differences in endemicity and not by known molecular markers of drug resistance. J Infect Dis 193:978-86